177 related articles for article (PubMed ID: 10692217)
1. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining.
Kitazume H; Kitamura K; Mukai K; Inayama Y; Kawano N; Nakamura N; Sano J; Mitsui K; Yoshida S; Nakatani Y
Cancer; 2000 Feb; 90(1):55-60. PubMed ID: 10692217
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless.
Simsir A; Fetsch P; Mehta D; Zakowski M; Abati A
Diagn Cytopathol; 1999 Mar; 20(3):125-30. PubMed ID: 10086235
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
5. Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
Kachali C; Eltoum I; Horton D; Chhieng DC
Semin Diagn Pathol; 2006 Feb; 23(1):20-4. PubMed ID: 17044192
[TBL] [Abstract][Full Text] [Related]
6. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
7. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
8. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
[TBL] [Abstract][Full Text] [Related]
9. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions.
Chhieng DC; Yee H; Schaefer D; Cangiarella JF; Jagirdar J; Chiriboga LA; Jagirdar J; Chiriboga LA; Cohen JM
Cancer; 2000 Jun; 90(3):194-200. PubMed ID: 10896333
[TBL] [Abstract][Full Text] [Related]
10. Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology.
Malle D; Valeri RM; Photiou C; Kaplanis K; Andreadis C; Tsavdaridis D; Destouni C
Acta Cytol; 2005; 49(1):11-6. PubMed ID: 15717748
[TBL] [Abstract][Full Text] [Related]
11. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
12. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical distinction between mesothelial and adenocarcinoma cells in serous effusions: a combination panel-based approach with a brief review of the literature.
Murugan P; Siddaraju N; Habeebullah S; Basu D
Indian J Pathol Microbiol; 2009; 52(2):175-81. PubMed ID: 19332905
[TBL] [Abstract][Full Text] [Related]
14. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
Leers MP; Aarts MM; Theunissen PH
Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
[TBL] [Abstract][Full Text] [Related]
16. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
[TBL] [Abstract][Full Text] [Related]
17. Utility of HBME-1 immunostaining in serous effusions.
Ascoli V; Carnovale-Scalzo C; Taccogna S; Nardi F
Cytopathology; 1997 Oct; 8(5):328-35. PubMed ID: 9313985
[TBL] [Abstract][Full Text] [Related]
18. Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.
Ferrandez-Izquierdo A; Navarro-Fos S; Gonzalez-Devesa M; Gil-Benso R; Llombart-Bosch A
Diagn Cytopathol; 1994; 10(3):256-62. PubMed ID: 7519540
[TBL] [Abstract][Full Text] [Related]
19. Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody.
Donna A; Betta PG; Bellingeri D; Tallarida F; Pavesi M; Pastormerlo M
Diagn Cytopathol; 1992; 8(4):361-5. PubMed ID: 1638937
[TBL] [Abstract][Full Text] [Related]
20. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]